Paclitaxel pharmacokinetics and pharmacodynamics
- PMID: 7597430
Paclitaxel pharmacokinetics and pharmacodynamics
Abstract
Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) displays nonlinear pharmacokinetics in humans. Both peak plasma paclitaxel concentrations and areas under the curve (AUCs) of the concentration versus time profiles will change disproportionately to changes in dose. Models that accurately describe the plasma paclitaxel profile contain two separate saturable processes, both described by Michaelis-Menten kinetics. Pharmacokinetic models using only linear components ultimately fail to describe adequately the disposition of paclitaxel in the body. The major toxicity of paclitaxel, neutropenia, appears to be related to the duration of time that plasma paclitaxel concentrations are at or above a threshold value. This relationship is well described by a sigmoid-Emax (maximum effect) model. Neutropenia is not directly related to either peak paclitaxel plasma concentration or to paclitaxel areas under the curve. A relationship between therapeutic efficacy and paclitaxel disposition is, as yet, undefined.
Similar articles
-
Bioanalysis, pharmacokinetics, and pharmacodynamics of the novel anticancer drug paclitaxel (Taxol).Semin Oncol. 1994 Oct;21(5 Suppl 8):53-62. Semin Oncol. 1994. PMID: 7939764 Review.
-
Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group.Clin Cancer Res. 2007 Nov 1;13(21):6410-8. doi: 10.1158/1078-0432.CCR-07-0064. Clin Cancer Res. 2007. PMID: 17975154
-
Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion.Clin Cancer Res. 1995 Jun;1(6):599-606. Clin Cancer Res. 1995. PMID: 9816021 Clinical Trial.
-
Phase I study of paclitaxel administered as a 1-hour infusion: toxicity and pharmacokinetics.Semin Oncol. 1997 Dec;24(6 Suppl 19):S19-16-S19-19. Semin Oncol. 1997. PMID: 9427259 Clinical Trial.
-
A review of the pharmacokinetics and pharmacodynamics of combination carboplatin/paclitaxel.Semin Oncol. 1997 Feb;24(1 Suppl 2):S2-85-S2-90. Semin Oncol. 1997. PMID: 9045345 Review.
Cited by
-
Chemotherapeutic properties and side-effects associated with the clinical practice of terpene alkaloids: paclitaxel, docetaxel, and cabazitaxel.Front Pharmacol. 2023 May 9;14:1157306. doi: 10.3389/fphar.2023.1157306. eCollection 2023. Front Pharmacol. 2023. PMID: 37229270 Free PMC article. Review.
-
In Vitro Systematic Drug Testing Reveals Carboplatin, Paclitaxel, and Alpelisib as a Potential Novel Combination Treatment for Adult Granulosa Cell Tumors.Cancers (Basel). 2021 Jan 20;13(3):368. doi: 10.3390/cancers13030368. Cancers (Basel). 2021. PMID: 33498451 Free PMC article.
-
Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker.Cancer Chemother Pharmacol. 2020 Oct;86(4):535-545. doi: 10.1007/s00280-020-04145-6. Epub 2020 Sep 18. Cancer Chemother Pharmacol. 2020. PMID: 32948918 Free PMC article.
-
Quantitation of paclitaxel, and its 6-alpha-OH and 3-para-OH metabolites in human plasma by LC-MS/MS.J Pharm Biomed Anal. 2019 Aug 5;172:26-32. doi: 10.1016/j.jpba.2019.04.027. Epub 2019 Apr 15. J Pharm Biomed Anal. 2019. PMID: 31022613 Free PMC article.
-
Microtechnology-Based Multi-Organ Models.Bioengineering (Basel). 2017 May 21;4(2):46. doi: 10.3390/bioengineering4020046. Bioengineering (Basel). 2017. PMID: 28952525 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources